Intraperitoneal (IP) catheters linked to subcutaneous portals have made routine intracavitary chemotherapy or immunotherapy safe and convenient. The IP route is anatomically appropriate for adjuvant or palliative treatment of intracavitary disease. IP chemotherapy has been successfully applied to ovarian, mesothelial, and gastrointestinal tumors.
Data shows that IP divinyl ether/maleic anhydride copolymer. MVE-2 (MW 15,000), has distinct localizing and toxicologic differences from that given intravenously (IV). When MVE-2 is given IV renal injury is observed; this is not seen on IP administration. The highest IP concentrations are found in mediastinal and mesenteric nodes, thymus and testis while the highest IV MVE-2 accumulation is found in the liver, spleen, adrenal, and kidney.
The IP route for treatment of tumors allows for high local tumoricidal drug concentrations or for regionalized immunostimulation with activating polymers or leukokines. The IP space can provide an antitumor, and antiviral immunizing site and/or a source of activated antitumor peritoneal exudate cells. The use of IP chemotherapy readily permits systemic neutralization of drug toxicity and can provide high portal venous concentrations of drug for the treatment of early liver metastasis.
This review speaks to the convenience and safety of the IP intracavitary route which provides a new option for the clinical utilization of polymers where regionalized abdominal effects and improved therapeutic index are warranted. The biologic application of IP polymers requires polymer distribution and kinetic studies which will provide unique tissue concentrations for application to immunization, cancer treatment and other diseases.
Get full access to this article
View all access options for this article.
References
1.
W. Regelson and G. Parker, Cancer Investigation4, in press (1986).
2.
S.B. Howell, Intra-arterial and Intracavitary Cancer Chemotherapy, 153-166, Nijhoff , Boston (1984).
3.
K. Antman, R. Osteen, D. Montella, Ibid., 167-177 (1984).
4.
R.F. Ozols, J.L. Speyer, and J. Jenkins, et al., Cancer Treatment Rep., 68, 1229-1232 (1984 ).
5.
J. Jenkins, P.H. Sugarbaker, and E.J. Gianola, et al., Surg. Gynecol. Obstet., 154, 858-864 (1979).
6.
J.W. Gyves, W.D. Ensminger, and J.E. Niederhuber , et al., JAMA, 251, 2538-2541 (1984).
7.
W. Harvey, F. Lombardo, and K. Reed, Proc. ASCO, 3, C-430 (1984).
8.
E.F. Van Leeliwen , E.J. Krul, and N.E. Langeveld, et al., Proc. ASCO, 3, C-431 (1984).
9.
R.M. Ottenbrite and A.M. Kaplan, "Some Biologically Active Copolymers of Maleic Anhydride," Ann. New York Acad. Sci., 446, 160 (1985).
10.
R. Duncan and J. Kopecek, Adv. in Polymer Sci., 57, 51-101 (1984).
11.
R.E. Falk, L. Makowka, N.A. Nossal, J. Falk, L.E. Rotstein, L.E. Fields, and S.S. Asculai, J. Surg. Res., 28, 485-491 (1980).
12.
B. Ardalen , J. Kotarac, H.J. Hrischikeshaven, R. Kibbe, G.E. Paget, Proc. Am. Assoc. Cancer Res., 26, Abs. 70, 18 (1985).
13.
J.J. Rinehart , D.C. Young, and J.A. Neidhardt, Cancer Res., 3, 2358-62 (1983).
14.
A. Rios, M. Rosenblum, M. Powell, et al., Cancer Treat. Rep., 67, 239-243 (1983).
15.
P.S. Morahan , D.W. Barnes, and A.E. Munson, Cancer Treat. Rep., 62, 1797-1805 (1978).
16.
J.E. Talmadge , A.E. Maluish, M. Collins, et al., J. Biol. Resp. Modif., 3, 1-19 (1984).
17.
M.G. Rosenblum , E.M. Hersh, and T.L. Loo, J. Chromatography Biomed. Appl., 272, 200-204 (1983).
18.
R.A. Carrano , J.D. Iuliucci, and J.K. Luce, et al., Immune Modulation Agents and Their Mechanisms, 243-260, Marcel Dekker, New York (1984).
19.
J.R. Baldwin , R.A. Carrano, A.R. Imondi, J.D. Iuliucci, and L.M. Hagerman, Polymeric Materials Science and Engineering, 51, 136-140 (1984).
20.
J.L. Speyer and C.E. Meyers, Cancer Chemo- and Immunopharmacology. I Chemopharmacology, p. 264-269, Springer-Verlag , New York (1980).
21.
R.L. Dedrick , C.E. Myers, and P.M. Bungay, et al., Cancer Treat. Rep., 62, 1-13 (1978).
22.
R.B. Jones, C.E. Myers, A.M. Guarino, et al., Cancer Chemother. Pharmacol. 1, 161-166 (1978 ).
S.J. Mohr and M.A. Chirigos, Immune Modulation and Control of Neoplasia by Adjuvant Therapy ( Progr. Cancer Res. Ther. Series V7), 415-426, Raven Press (1978).
49.
M.A. Chirigos and W.A. Stylos, Cancer Res., 40, 1967-1972 (1980).
50.
P.S. Roberts and W. Regelson, Control of Neoplasia by Modulation of the Immune System, 549-562, Raven Press (1977).
51.
W.B. Van DenBerg, A.C.M. Th .Van Maarsseveen, and H. Mullink, et al., J. Path . 132, 23-33 (1980).
52.
W.B. Van den Berg, T.C. Haasakker, and A.C.M. Th.Van Maarsseven, Immunol., 40, 673-681 (1980).
53.
E.S. Kleinerman , R. Zicht, and R.H. Wiltrout, et al., AACR Abs., 25, 1036 (1984 ).
54.
E.M. Hersh, J. Gutterman, and G. Mavligit, et al., Adv. in Immuno Pharmacology, 227-234, Pergamon Press (1981).
55.
C.H. Evans , J.H. Ransom, and J.A. Heinbaugh, AACR Abst., 25, 1063 (1984 ).
56.
J. Ransom, L. Cleveland, and R. McCabe, et al., AACR Abs., 25, 936 (1984).
57.
M. Chirigos, V. Papademetriou, and A. Bartocci, et al., Adv. in Immunopharmacology, 217-225, Pergamon Press (1981).
58.
J. Berek, R. Knapp, and N. Hacker, et al., Proc. ASCO, 3, E-674 (1984).
59.
S.P. Richman , E. M. Hersh, and J.U. Gutterman, et al., Cancer Treat. Rpts., 65, 383-387 (1981).
60.
A.E. Senyei and K.J. Widder, Gyn. Oncol., 12, 1-13 (1981).
61.
J. Folkman , S. Taylor, and C. Spillberg, Ciba Foundation Symp., 100, 132-149 (1983).
62.
H.S. Goldsmith , A.L. Griffith, A. Kupfreman, and N. Katsimpoolas, JAMA252, 2034-2036 (1984).
63.
W. Regelson , Adv. in Chemotherapy, 3, 303-357 (1968).
64.
W. Regelson , Hematol. Rev., 1, 193-227 (1968).
65.
D.R. Black , F. Eckstein, E. DeClercq, and T.C. Merigan, Chemother., 3, 198-206 (1973).
66.
P.S. Morahan , A.E. Munson, W. Regelson, S.L. Commerford, and L.D. Hamilton, Proc. Nat. Acad. Sci., USA, 69, 842-846 (1972).
67.
F.S. Philips , M. Fleisher, L.D. Hamilton, N.K. Schwartz, and S.S. Stem-berg, Biological Effects of Polynucleotides, 259-273, Springer-Verlag, New York (1971).
N.R. DiLuzio , J.A. Cook, C. Cohen, J. Rodregue, P. Kakoshis, and R.B. McNamee, Progr. Cancer Res. Ther., 7, 171-182 (1978).
70.
S. Ormai, A. Hagenbeek, M. Paklouits, and D.W. Van Bekkum , Cell Tiss. Kinet., 6, 406-423 (1973).
71.
W. Regelson, Adv. Cancer Res., 11, 223-287 (1968).
72.
W. Regelson, B.I. Shnider, J. Colsky, K.B. Olson, J.F. Holland, C.L. Johnston, Jr., and L.H. Dennis, Immune Modulation and Control of Neoplasia by Adjuvant Therapy, p. 469-490, Raven Press, New York (1978).
73.
E. Mihich, C.L. Simpson, W. Regelson, and P.I. Mulhern, Fed. Proc., 19, A-142 (1960).
74.
K.S. Kunke and R.C. Strunk, JNCI, 66, 141-146 (1981).
75.
K.E. Barrett and F.L. Pearce, Agents and Actions, 12, 186-189 (1982).
76.
F.A. Mukhtar , F.S. Hoffmeister, J. DiPaolo, J. Bross, P. Sheehe, H. Wilkens, and G.E. Moore, Am. J. Surg., 106, 768-776 (1963).
77.
Z.J. Twardowski , K.D. Nolph, T.J. McGary, and H.L. Moore, Artificial Organs, 7, 420-427 (1983).
78.
Y. Skornick , A.R. Dresdale, and W.F. Sindelar, JNCI, 70, 465-7 (1983).
79.
M. Markman , S.B. Howell, and C.E. Pfeifle, et al., Proc. ASCO3, C-643 (1984 ).
80.
G.D. Hart and M.L. Soots, Applied Therapeutics, 10, 760-762 (1968).
81.
J.L. Speyer , J.M. Collins, and R.L. Dedrick, et al., Cancer Res., 40, 567-572 (1980).
82.
J.L. Speyer , P.H. Sugarbaker, and J.M. Collins, et al., Cancer Res., 41, 1916-1922 (1981).
83.
J.M. Collins , R.L. Dedrick, and F.G. King, et al., Clin. Pharmacol. Ther., 28, 235-246 (1980).
84.
G. Beretta, E. Scioli, and D. Tabiadon, Current Chemotherapy and ImmunotherapyProc. 12, Int. Congr. Chemotherapy, Florence, Italy, 1257-1259 (1981 ).
85.
S B.Howell, B.B.F. Chu, and W.E. Wung, et al ., Clin. Invest., 67, 1161-1170 (1981).
86.
S.B. Howell , C.L. Pfeifle, and W.E. Wung, et al., Ann. Int. Med., 97, 845-851 (1982).
87.
B. Jones, J.M. Collins, and C.E. Myers, et al., Cancer Res., 41, 55-59 (1981).
88.
R.F. Keeford , S.L. Woods, and R.M. Fox, et al., Med. J. Aust., 2, 447-448 (1980).
89.
R.F. Ozols , R.C. Young, and J.L. Speyer, et al., Cancer Res., 42, 4265-4269 (1982).
90.
J. Roboz, A.J. Jacobs, and J.F. Holland, et al., Medical and Pediatric Oncology, 9, 245-250 (1981).
91.
M. Markman , S.B. Howell, and W.E. Lucas, et al., J. Clin. Oncol., 2, 1321-1326 (1984).
92.
M E.King, C.E.Pfeifle, and S. B. Howell, J. Clin. Oncol., 2, 662-669 (1984).
93.
R F.Ozols, J.K.V. Willson, and M.D. Weltz, et al., Cancer Res., 40, 4109-4112 (1980 ).
94.
R.F. Ozols , G.Y. Locker, and J.H. Doroshow, et al., Cancer Treatment Rpts., 63, 269-273 (1979).
95.
B.K. Chang, Bull. Cancer (Paris), 69, 172-175 (1982).
96.
P. H. Sugarbaker and C. E. Meyers, NCI Clin. Project # 79-L-28 (1979).
97.
P. H. Sugarbaker, NCI Clin. Project proposed (1979).
98.
M. Shea, J. Koziol, and S.B. Howell, Clin. Pharmacol. Ther., 35, 419-425 (1984).
99.
C. Breedis and G. Young, Am. J. Path., 30, 969-977 (1954).
100.
K.F. Aronson , C. Hellenkant, and J. Holmberg, et al., European J. Surgical Res., 11, 99-106 (1979).
101.
S. Dakhil, W. Ensminger, and K. Cho, et al., Cancer, 50, 631-5 (1982).
102.
W. Regelson and G. Parker, Cancer Investigation, in press (1986).
103.
B. Fisher, NBSAP Protocol, C-02 (1985).
104.
I. Taylor , P. Brooman, and J.T. Rowling, Br. Med. J., 2, 1320-1322 (1977).
105.
L.R. Laufman , T.A. Nims, and J.T. Guy, et al., J. Clin. Oncol., 2, 1382-1389 (1984).
106.
C.E. Myers and J.M. Collins, Cancer Investigation, 1, 395-401 (1983).
107.
N.R. Dunnick , R.B. Jones, and J.L. Doppman, et al., Am. J. RoentgenoL, 133, 221-223 (1979).
